专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20200138288A cMET 모노클로날 결합제의 약물 접합체, 및 그의 용도 审中-公开
公开(公告)号：KR20200138288A
公开(公告)日：2020-12-09
申请号：KR20207030339
申请日：2019-03-27
申请人： MITSUBISHI TANABE PHARMA CORP
发明人： CORONELLA JULIA , GYMNOPOULOS MARCO , BLOT VINCENT , FUJITA RYO , NEWMAN ROLAND
IPC分类号： A61K47/68 , A61K31/5517 , A61K39/00 , A61P35/00 , C07K16/28
摘要： 본원에서제시되는것은피롤로벤조디아제핀독소에접합되어있는신규한모노클로날 cMET 결합제, 그의조성물및 암의치료를위한그의용도이다.

2. 发明公开

KR20180041662A 신규 이미드 유도체 및 그 의약으로서의 용도 审中-公开
公开(公告)号：KR20180041662A
公开(公告)日：2018-04-24
申请号：KR20187002493
申请日：2016-07-08
申请人： MITSUBISHI TANABE PHARMA CORP
发明人： ISHIBUCHI SEIGO , SARUTA KUNIO , HAMADA MAIKO , MATOBA NOBUATSU , MATSUDAIRA TETSUJI , SEKI MAKI , TARAO AKIKO , HONJO TAKASHI , OGATA SHINGO , KAWATA ATSUSHI , MOROKUMA KENJI , FUJIE NAOTO , AOYAMA YUKIO
IPC分类号： C07D401/14 , A61K31/496 , A61K31/497 , A61P1/04 , A61P19/02 , C07D403/14 , C07D405/14 , C07D409/14 , C07D471/04 , C07D487/04
CPC分类号： A61K31/4178 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/501 , C07D233/78 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04
摘要： 본발명은, 항상형 MMP-2의생성보다도유도형 MMP, 특히 MMP-9의생성을억제하는신규한저분자화합물을제공하는것을목적으로한다. 본발명은, 하기식 (I)로표시되는화합물에관한것으로, 이화합물은선택적인 MMP-9 생성억제작용을가지며, 관절류머티즘등의자가면역질환, 염증성장질환(궤양성대장염, 크론병), 변형성관절증의예방약및/또는치료약으로서유용하다.[식중, 각각의기호는명세서에기재된바와같다.]

3. 发明公开

KR20180057651A 가교된 핵산 GUNA, 이의 제조 방법 및 중간체 화합물 审中-公开
公开(公告)号：KR20180057651A
公开(公告)日：2018-05-30
申请号：KR20187010564
申请日：2016-09-20
申请人： MITSUBISHI TANABE PHARMA CORP , UNIV OSAKA
发明人： OBIKA SATOSHI , KAWANISHI EIJI , SAWAMOTO HIROAKI , YAMAKOSHI SHUHEI , ARAI YUUKI , KUMAGAI SHINJI
IPC分类号： C07H19/06 , C07H9/06 , C07H19/16 , C07H21/00
CPC分类号： C07H9/06 , C07H19/06 , C07H19/16 , C07H21/00
摘要： 본발명은구아니딘가교형인공핵산 (이하 GuNA 로약칭됨) 의제조방법, 및이의제조를위한중간체화합물을제공한다. 특히, 본발명은일반식 II 로나타나는화합물 (화학식에서, R, R, R, R, R, R, m, 및고리 A' 는명세서에정의된바와같음) 과환원제가반응하는, 일반식 I 로나타나는화합물또는이의염 (화학식에서, R, R, R, R, R, R, m 및고리 A 는명세서에정의된바와같음) 의제조방법을제공한다.

4. 发明申请

WO2012094283A3 BEPOTASTINE COMPOSITIONS 审中-公开
公开(公告)号：WO2012094283A3
公开(公告)日：2012-07-12
申请号：PCT/US2012/020028
申请日：2012-01-03
申请人： ISTA PHARMACEUTICALS, INC. , MITSUBISHI TANABE PHARMA, CORP. , PADILLA, Angel , BAKLAYAN, George
发明人： PADILLA, Angel , BAKLAYAN, George
IPC分类号： A61K9/12 , A61K31/444 , A61P11/02 , A61P11/00
摘要： Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.

5. 发明申请

WO2009156860A3 4-(PYRIDIN-4-YL)-1H-(1, 3, 5)TRIAZIN-2-ONE DERIVATIVES AS GSK3-BETA INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译： 4-（PYRIDIN-4-YL）-1H-（1,3,5）TRIAZIN-2-ONE衍生物作为用于治疗神经损伤性疾病的GSK3-β抑制剂
公开(公告)号：WO2009156860A3
公开(公告)日：2010-03-04
申请号：PCT/IB2009006463
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
IPC分类号： C07D401/04 , A61K31/53 , A61P3/10 , A61P25/28 , A61P33/06 , A61P35/00 , C07D487/04
CPC分类号： C07D401/04 , C07D487/04
摘要： A triazinone derivative represented by formula (I) wherein: Z represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a Ci-ß alkoxy group; R1 represents a 4-pyridine ring; R2 represents a hydrogen atom, a C1-6 alkyl; R3 represents a hydrogen atom, a C1-6 alkyl group; R2 and R3 may form together a 6 membered cycle with the nitrogens caring R2 and R3 optionally substituted; R4 represents: a phenyl ring, being optionally substituted; n represents 0 to 2; in form of a free base or of an addition salt with an acid. The compounds of the present invention have GSK3ß inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activity of GSK3ß and more particularly of neurodegenerative diseases.
摘要翻译：由式（I）表示的三嗪酮衍生物，其中：Z表示键，羰基，任选被一个或两个选自C 1-6烷基，羟基，C 1-6烷氧基的基团取代的亚甲基; R1表示4-吡啶环; R2表示氢原子，C1-6烷基; R3表示氢原子，C1-6烷基; R2和R3可以一起形成6元环与关心R2和R3任选取代的氮; R4表示：任选被取代的苯环; n表示0〜2; 以游离碱的形式或与酸形成的加成盐。本发明的化合物具有GSK3β抑制活性，可用作用于预防和/或治疗由GSK3β的异常活性引起的疾病，特别是神经变性疾病的药物的活性成分。

6. 发明申请

WO2009064836A3 KYNURENINE-AMINOTRANSFERASE INHIBITORS 审中-公开
标题翻译： KUNURENINE-AMINOTRANSFERASE抑制剂
公开(公告)号：WO2009064836A3
公开(公告)日：2009-07-02
申请号：PCT/US2008083321
申请日：2008-11-13
申请人： UNIV MARYLAND , MITSUBISHI TANABE PHARMA CORP , SCHWARCZ ROBERT , KAJII YASUSHI , ONO SHIN-ICHIRO
发明人： SCHWARCZ ROBERT , KAJII YASUSHI , ONO SHIN-ICHIRO
IPC分类号： C07D401/10 , C07D401/06 , C07D403/02
CPC分类号： C07D498/06 , C07D215/56 , C07D401/04
摘要： Compounds of formula (I) : prodrug derivatives and/or pharmaceutically acceptable salt thereof, selectively inhibit the enzyme kynurenine aminotransferase, thereby reducing the synthesis of kynurenic acid. The compounds are used for the treatment of psychiatric and neurological diseases which benefit from an increase in glutamatergic and/or cholinergic neurotransmission, such as schizophrenia, depression, bipolar illness, anxiety and Alzheimer's disease. Furthermore, the compounds of the invention are useful for stimulating attention, memory and other cognitive processes in normal individuals of any age, including children, adolescents and the elderly. Additionally, the compounds of the invention are also useful for treatment of patients suffering from malaria by preventing parasite gametogenesis and fertility based on reduction of xanthurenic acid formation from its bioprecursor 3 -hydroxy kynurenine.
摘要翻译：式（I）化合物：前药衍生物和/或其药学上可接受的盐选择性地抑制犬尿氨酸转氨酶，由此减少犬尿烯酸的合成。该化合物用于治疗精神病和神经疾病，这些疾病受益于谷氨酸能和/或胆碱能神经传递的增加，如精神分裂症，抑郁症，双相情感障碍，焦虑和阿尔茨海默病。此外，本发明化合物可用于刺激任何年龄的正常个体，包括儿童，青少年和老年人的注意力，记忆力和其他认知过程。此外，本发明化合物还可用于通过防止寄生虫配子发生和基于从其生物前体3-羟基犬尿氨酸形成黄原酸形成的可育性来治疗患有疟疾的患者。

7. 发明申请

WO2008155666A3 HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：用于治疗神经损伤性疾病的异氟醚取代的吡咯烷酮衍生物
公开(公告)号：WO2008155666A3
公开(公告)日：2009-04-09
申请号：PCT/IB2008002429
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , CHEREZE NATHALIE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： CHEREZE NATHALIE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
IPC分类号： C07D239/38 , A61K31/495 , A61P3/00 , A61P25/00 , A61P35/00 , C07D401/14 , C07D403/14 , C07D409/14 , C07D417/14 , C07D471/04
CPC分类号： C07D403/14 , C07D239/38 , C07D401/14 , C07D409/14 , C07D417/14 , C07D471/04
摘要： A pyrimidone derivative represented by Formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Formula (I). The compounds (I) are suitable for the treatment of neurodegenerative diseases.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物：式（I）。化合物（I）适用于治疗神经变性疾病。

8. 发明申请

WO2009035159A1 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR 审中-公开
标题翻译： 3-（（2S）-2-（4-（3-甲基-L，2,4-氧杂吖唑-5-基）苯基）吗啉）-6-（吡咯烷-4-基）嘧啶-2 （3H） - 酮作为TAU蛋白激酶抑制剂
公开(公告)号：WO2009035159A1
公开(公告)日：2009-03-19
申请号：PCT/JP2008066929
申请日：2008-09-12
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , SAKAI DAIKI , WATANABE KAZUTOSHI
发明人： SAKAI DAIKI , WATANABE KAZUTOSHI
IPC分类号： C07D413/14 , A61K31/5377 , A61P25/00
CPC分类号： C07D413/14
摘要： A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐：用于预防和/或治疗由tau蛋白激酶1的异常活性（例如神经变性疾病（例如阿尔茨海默病））引起的疾病。

9. 发明申请

WO2008155668A3 HETEROARYLAMIDE PYRIMIDONE COMPOUNDS 审中-公开
标题翻译：异丁酰胺吡咯烷酮化合物
公开(公告)号：WO2008155668A3
公开(公告)日：2009-03-12
申请号：PCT/IB2008002445
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
IPC分类号： C07D401/12 , A61K31/513 , A61P3/00 , A61P25/00 , C07D239/36 , C07D403/12 , C07D405/12 , C07D409/12
CPC分类号： C07D403/12 , C07D239/36 , C07D401/14 , C07D405/14 , C07D409/14 , C07D471/04
摘要： A pyrimidone derivative represented by Formula (I) or a salt, solvate or a hydrate thereof, wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 4 or 5-pyrimidine ring or a 4- pyridine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a 4-15 membered heterocyclic, group, this group being optionally substituted by 1 to 4 substituents as defined in claim 1; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom or a C1-6 alkyl group;. R5 represents a hydrogen atom, a C1-6 alkyl group; R6 represents a hydrogen atom, ' a C1-6 alkyl group;. R7 represents a hydrogen atom or a C1-6 alkyl group; and n represents 0 to 3 and m represents 1 in the form of a free base or of an addition salt with an acid. and a medicament containing the same as a GSKk inhibitor.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐，溶剂合物或水合物，其中：X表示两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z表示键，氧原子，被氢原子或C1-3烷基取代的氮原子，硫原子，任选被一个或两个选自C 1-6烷基，羟基的基团取代的亚甲基基团，C1-6烷氧基，C1-2全卤代烷基或氨基; R1表示2,4或5-嘧啶环或4-吡啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示4-15元杂环基，该基团任选被1至4个如权利要求1所定义的取代基取代; R3表示氢原子，C1-6烷基或卤素原子; R4表示氢原子或C1-6烷基。 R5表示氢原子，C1-6烷基; R6表示氢原子，C1-6烷基。 R7表示氢原子或C1-6烷基; n表示0〜3，m表示1以游离碱或与酸形成的加成盐的形式。和含有与GSKk抑制剂相同的药物。

10. 发明申请

WO2008155670A2 ARYLAMIDE PYRIMIDONE COMPOUNDS 审中-公开
标题翻译： ARYLAMIDE PYRIMIDONE化合物
公开(公告)号：WO2008155670A2
公开(公告)日：2008-12-24
申请号：PCT/IB2008002458
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
CPC分类号： C07D403/04 , A61K9/0019 , A61K9/2018 , A61K9/4858 , C07D413/14
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 4 or 5-pyrimidine ring or a 4-pyridine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a benzene ring, a naphthalene ring or a benzyl group; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, an heteroaryl group optionally substituted by a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, C1-6 alkoxy group optionally substituted by a C3-5 cycloalkyl group, a C1-2 perhalogenated alkoxy group, a C1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group or a C2-12 dialkylamino group, an acetoxy group or an aminosulfonyl group; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom or a C1-6alkyl group; R5 represents a hydrogen atom, a C1-6 alkyl group; R6 represents a hydrogen atom, a C1-6 alkyl group; R7 represents a hydrogen atom or a C1-6 alkyl group; n represents 0 to 3 and m represents 1 in the form of a free base or of an addition salt with an acid.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物：其中X表示两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z表示键，氧原子，被氢原子或C1-3烷基取代的氮原子，硫原子，任选被一个或两个选自C 1-6烷基，羟基的基团取代的亚甲基基团，C1-6烷氧基，C1-2全卤代烷基或氨基; R1表示2,4或5-嘧啶环或4-吡啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示苯环，萘环或苄基; 该环任选被1至4个选自C 1-6烷基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，卤素原子，C 1-2全卤代烷基， C 1-3卤代烷基，羟基，任选被C 1-6烷基取代的杂芳基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，任选被 C3-5环烷基，C1-2全卤代烷氧基，C1-6烷基磺酰基，硝基，氰基，氨基，C1-6单烷基氨基或C2-12二烷基氨基，乙酰氧基或氨基磺酰基; R3表示氢原子，C1-6烷基或卤素原子; R4表示氢原子或C1-6烷基; R5表示氢原子，C1-6烷基; R6表示氢原子，C1-6烷基; R7表示氢原子或C1-6烷基; n表示0〜3，m表示1以游离碱或与酸的加成盐形式的1。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式